News Releases
Schizophrenia, Bipolar Disorder Rx Approved
DUBLIN and BUDAPEST, Hungary, Sept. 17, 2015 /PRNewswire/ -- Allergan plc (NYSE: AGN) and Gedeon Richter Plc. announced today that the U.S. Food and Drug Administration (FDA) has approved VRAYLAR™ (cariprazine) capsules, an atypical antipsychotic, for the acute treatment of manic or mixed episodes associated with bipolar I disorder and for treatment of schizophrenia in adults.
FDA Approves New Schizophrenia Rx
There’s a new treatment option for schizophrenia – INVEGA TRINZATM (three-month paliperidone palmitate), the first and only schizophrenia medication to be administered just four times a year, providing the longest dosing interval available.
FDA Approves Abilify Maintena for Schizophrenia
The US Food and Drug Administration (FDA) has approved ABILIFY MAINTENA™ (aripiprazole) for extended release injectable suspension, an intramuscular (IM) depot formulation indicated for the treatment of schizophrenia.
FDA Approves Adasuve for Agitation with Schizophrenia, Bipolar I
Alexza Pharmaceuticals, Inc. announced today that the US Food and Drug Administration (FDA) approved Adasuve ( loxapine ) Inhalation Powder 10 mg for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults.